Published in:
09-04-2024 | Gastric Cancer | ASO Author Reflections
ASO Author Reflections: Preoperative Chemotherapy Provides Survival Benefits Compared with Upfront Surgery for Patients with Liver-Limited Metastasis from Gastric Cancer
Authors:
Yuki Hirose, MD, Masaki Aizawa, MD, Hiroshi Yabusaki, MD, Tatsuya Nomura, MD, Kabuto Takano, MD, Takashi Kawasaki, MD, Gen Watanabe, MD, Yukio Shimojima, MD, Kizuki Yuza, MD, Takeo Bamba, MD, Satoru Nakagawa, MD
Published in:
Annals of Surgical Oncology
|
Issue 6/2024
Login to get access
Excerpt
Systemic chemotherapy has served as the primary therapeutic modality for liver metastasis from gastric cancer (GC), whereas some retrospective studies have suggested that surgical resection for liver-limited metastasis (LLM) from GC may confer relatively favorable long-term survival, particularly in the case of solitary LLM.
1‐3 Nevertheless, nearly 50% of patients with LLM exhibit early recurrence within 1 year following curative-intent surgery.
1 Thus, it is prudent to administer preoperative chemotherapy for the purpose of controlling micrometastases and identifying patients who can benefit from surgery.
4 However, to date, no reports have comprehensively analyzed the efficacy of preoperative chemotherapy concerning its impact on long-term outcomes after hepatectomy for LLM from GC. …
